How to pass on wealth, AstraZeneca & Ceres: The Companies and Markets Show

·38 min·3 clips

AstraZeneca's US-UK push and the Great Wealth Transfer reveal how big pharma and baby boomers are reshaping markets and inheritances.

The episode opens with host Dan Jones introducing three segments: pharmaceutical updates, wealth transfer, and a company analysis. Julian Hoffman discusses recent US drug pricing developments, including a voluntary agreement between the Trump administration and Pfizer, which lifted uncertainty and boosted pharma stocks. He details AstraZeneca's supplemental biologics license application for its NHER2 breast cancer drug, which could become a first-line therapy and exceed $5 billion in sales. The conversation covers AstraZeneca's decision to enhance its US listing while maintaining UK headquarters, amid political pressures. GSK's CEO succession from Emma Walmsley to Luke Miels is analyzed as a natural transition after corporate restructuring. Val Cipriani then addresses the Great Wealth Transfer, explaining the trade-offs between lifetime gifting and inheritance, including the seven-year rule for tax exemption. She discusses concerns over care costs, annual gifting allowances, and strategies for fair distribution among children. Mark Robinson examines Ceres Power's interim results, noting downgraded revenue guidance and a loss, but highlights its solid oxide fuel cell technology. He covers the terminated Bosch joint venture, the ongoing Doosan partnership in South Korea, and potential applications in data centers and AI, despite competition from companies like Bloom Energy. The episode concludes with a summary of Ceres' financial position and market outlook.

As heard by us

Inheritance-tax timing sits alongside live questions around AstraZeneca, GSK and Serra's Power.

The Companies and Markets Show frames the Great Wealth Transfer as a matter of timing, control and family trade-offs, then sets that alongside two company stories still in motion.

Read the full review in PlayNext →

Why you'd press play

You get inheritance-tax trade-offs, AstraZeneca's US-UK push and pull, and a test of whether Serras Power still has a route to profitability.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Investors' Chronicle